DMAC Earnings Forecast
Looking ahead, DMAC remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of -0.16.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been Go Up by 16.24%. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in DMAC long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+16.24%
In Past 3 Month
Unlock the reason behind revisions!
Earnings Forecast
Revenue
EPS
Currency:
No data
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how DMAC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DMAC sees a -0.81% change in stock price 10 days leading up to the earnings, and a +8.10% change 10 days following the report. On the earnings day itself, the stock moves by +3.46%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -14.10% on the day following the earnings release and then changed by 44.53% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of DMAC's latest earnings report for FY2025Q3?
DMAC reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.17, surpassing the expected -0.15 by -13.33% . The stock experienced a -14.1% price change on the earnings day and a 9.35% change over the next five days, reflecting market reactions to the results.
How did DMAC's stock price react after the FY2025Q3 earnings release?
Following DMAC's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -14.10% on the day of the release. Over the subsequent five days, it saw a 9.35% change. Historically, DMAC's stock price tends to shift by an average of -0.81% in the 10 days leading up to earnings and +8.10% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for DMAC for undefined?
For , analysts estimate DMAC’s annual revenue to reach undefined, while the EPS is projected at -0.16. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.
How does DMAC's stock price correlate with earnings forecast revisions?
The correlation between DMAC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from DMAC's next earnings report?
Based on historical trends, DMAC's stock price typically moves by -0.81% in the 10 days before its earnings and +8.10% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.16 and revenue of undefined.
What is the sentiment in DiaMedica Therapeutics Inc (DMAC) Q3 2025 Earnings Call Summary?
The earnings call reveals a mixed sentiment. While there is progress in clinical trials and a strong cash position due to private placement, increased expenses and net losses are concerning. The Q&A section highlights positive drug safety feedback and trial progression but lacks specifics on enrollment rates, indicating potential uncertainties. The absence of new partnerships or shareholder return plans further tempers enthusiasm. Given these factors, the stock price is likely to remain stable, suggesting a neutral sentiment.